Synthetic Consensus FSHR Immunogenic Composition for Ovarian Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ovarian cancer treatments have limited effectiveness, with 5-year survival rates remaining unchanged for decades, and existing immunotherapies struggle to enhance T-cell infiltration in tumors, highlighting a need for targeted therapies that can break immune tolerance to Follicle Stimulating Hormone Receptor (FSHR) without harming healthy tissues.
Innovation Solution
Development of an immunogenic composition comprising a nucleic acid molecule encoding a peptide with a high degree of identity to FSHR sequences, designed to induce a strong immune response by encoding amino acid sequences or immunogenic fragments that are at least 90% identical to specific SEQ ID NO: sequences, which can be administered via electroporation or injection to redirect T-cells against ovarian cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ovarian cancer treatments (surgery and chemotherapy) are used, then current standard of care is maintained, but 5-year survival rates remain unchanged for decades
Solution Approach 1:
The patent changes the fundamental parameter of treatment approach by transitioning from conventional surgery and chemotherapy to immunotherapy using synthetic consensus DNA vaccines. This parameter change targets the immune system's ability to recognize and attack ovarian cancer cells expressing FSHR, thereby improving survival rates without relying on traditional treatment modalities that have plateaued in effectiveness.
Solution Approach 2:
The patent introduces an intermediary mechanism - the synthetic consensus DNA vaccine encoding FSHR peptides - that mediates between the patient's immune system and the ovarian cancer cells. This intermediary enables the immune system to specifically recognize and attack FSHR-expressing cancer cells while sparing healthy tissues, thereby improving treatment effectiveness and survival rates.
2Reliability
If immunotherapies are used to enhance T-cell infiltration, then immune response is improved, but ability to break immune tolerance to FSHR is limited
Solution Approach 1:
The patent applies local quality by designing synthetic consensus sequences that locally modify FSHR peptide sequences to enhance immunogenicity. These localized modifications in specific regions of the FSHR protein sequence create epitopes that are more effectively recognized by the immune system, thereby breaking immune tolerance while maintaining specificity for FSHR-expressing cells.
Solution Approach 2:
The patent creates composite immunogenic compositions by combining synthetic consensus DNA sequences encoding FSHR peptides with adjuvants and delivery systems. This composite approach enhances the overall immunogenicity and ability to break immune tolerance, combining multiple functional elements to achieve superior immune activation compared to single-component approaches.
3Manufacturing precision
If FSHR is targeted as a therapeutic antigen, then selective targeting of ovarian cancer is achieved, but potential toxicity to healthy tissues expressing FSHR must be avoided
Solution Approach 1:
The patent applies partial action by focusing the immune response on specific epitopes and regions of the FSHR protein that are most immunogenic and most highly expressed in ovarian cancer cells. By targeting specific portions rather than the entire FSHR molecule, the therapy achieves high specificity for cancer cells while minimizing potential toxicity to healthy FSHR-expressing tissues through the oophorectomy procedure.
Data Source
AI summary
Provided herein is an immunogenic composition comprising a synthetic consensus antigen to Follicle Stimulating Hormone Receptor (FSHR) protein which is abundant in many ovarian cancer sub-types. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.